PaxMedica, Inc. (PXMD)
| Market Cap | 88.39K -86.0% |
| Revenue (ttm) | n/a |
| Net Income | -13.49M |
| EPS | -1.91 |
| Shares Out | 126.28M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,965 |
| Open | 0.0005 |
| Previous Close | n/a |
| Day's Range | 0.0005 - 0.0007 |
| 52-Week Range | 0.000001 - 0.0200 |
| Beta | -30.84 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 16, 2026 |
About PaxMedica
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is dev... [Read more]
Financial Performance
Financial StatementsNews
PaxMedica announces receives notification to grant patent right in China
PaxMedica (PXMD) has received a Notification to Grant Patent Right for Chinese Invention Patent Application No: 2020800553323, Compositions and methods for treating cognitive, social, or behavioral di...
PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions
PaxMedica, Inc. (OTC PINK:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, is pleased to announce it has received a Notification to Grant...
PaxMedica secures immediate exercise of warrants
PaxMedica announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 4,423,080 shares of common stock of the originally...
PaxMedica Secures Immediate Exercise of Warrants
TARRYTOWN, NY / ACCESSWIRE / September 3, 2024 / PaxMedica, Inc. (OTC PINK:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announc...
PaxMedica reports first patient treated with PAX-101 for HAT
PaxMedica announced a significant milestone in its global health efforts. The Malawi Ministry of Health has informed the company that a patient suffering from the potentially fatal parasitic infection...
PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection
Company provides update on regulatory progress towards US NDA submission TARRYTOWN, NY / ACCESSWIRE / August 27, 2024 / PaxMedica, Inc. (OTC PINK:PXMD), a clinical-stage biopharmaceutical company dedi...
PaxMedica files Nasdaq delisting appeal notice
PaxMedica announced it has timely filed a formal notice of appeal with the Nasdaq Office of Appeals and Review to reverse the decision of a Nasdaq Hearings Panel to delist…
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101
TARRYTOWN, New York, May 15, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (the “Company” or “PaxMedica”) ( OTC:PXMD), a biopharmaceutical company dedicated to advancing treatments for neurolog...
PaxMedica prepares to file NDA for use of suramin in HAT
PaxMedica provided a corporate update in light of its transition off the NASDAQ stock market, emphasizing this change will not affect the company’s commitment to advancing treatments for neurological ...
PaxMedica responds to emergency request for IV suramin
PaxMedica expects to take immediate action in response to an urgent request for IV suramin from the Ministry of Health of Malawi, a country in east Africa. The request seeks…
PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
TARRYTOWN, New York, April 23, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica Inc. (Nasdaq: PXMD) (the “Company”), a leading biopharmaceutical company dedicated to advancing treatments for neurological ...
PaxMedica announces request from MOH for emergency access to IV suramin
PaxMedica announced it has received an urgent request from the Ministry of Health, or MOH, of Malawi, asking for emergency access to IV suramin to avert a potential humanitarian crisis…
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
TARRYTOWN, New York, April 16, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica , Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today ann...
Why is PaxMedica (PXMD) stock surging today?
PaxMedica (NASDAQ: PXMD) has surged by 92.7% so far on Friday, reflecting the market's positive reaction to the company's announcement of significant progress in its drug development efforts.
PaxMedica provides update on potential PAX-101 NDA submission
PaxMedica announced the completed execution of its three registration/validation batches of PAX-101, an IV formulation of suramin. The company said this achievement is an important milestone to enabli...
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
TARRYTOWN, New York, April 11, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica , Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announ...
PaxMedica releases lastest company presentation
PaxMedica announced the release of its latest company presentation. This comprehensive overview showcases PaxMedica’s strategic direction, recent advancements in ASD therapeutics, and its commitment t...
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments
TARRYTOWN, New York, March 13, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced...
PaxMedica Releases Fireside Chat Video with CEO Howard Weisman
TARRYTOWN, NY / ACCESSWIRE / December 6, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, announced the release of a Firesi...
PaxMedica initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of PaxMedica with a Buy rating and $3 price target. The analyst says the company is developing novel formulations of suramin for treatment of neurological disorders…
PaxMedica Announces Closing of $7.0 Million Public Offering
TARRYTOWN, NY / ACCESSWIRE / November 22, 2023 / PaxMedica, Inc. (NASDAQ:PXMD) ("PaxMedica" or the "Company"), a biopharmaceutical company focused on advancing treatments for neurological disorders, t...
PaxMedica prices 5.38M shares at $1.30 in public offering
PaxMedica announced the pricing of its public offering of an aggregate of 5,384,615 shares of its common stock and warrants to purchase up to 5,384,615 shares of common stock, at…
PaxMedica Announces Pricing of $7.0 Million Public Offering
TARRYTOWN, NY / ACCESSWIRE / November 20, 2023 / PaxMedica, Inc. (NASDAQ:PXMD) ("PaxMedica" or the "Company"), a biopharmaceutical company focused on advancing treatments for neurological disorders, t...
PaxMedica Inc. Featured in Syndicated Broadcast Highlighting FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data
LOS ANGELES, Nov. 17, 2023 (GLOBE NEWSWIRE) -- via IBN –PaxMedica, Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announces that it ...
PaxMedica, Inc. Announces Third Quarter 2023 Financial Results and Business Update
TARRYTOWN, NY / ACCESSWIRE / November 15, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, announced today a comprehensive ...